Summary
a2 Milk Company has posted FY2026 revenue of NZ$1.975 billion (approximately RMB7.85 billion), up 12.4% year-on-year. Adjusted EBITDA increased 5.4% to NZ$308 million, while adjusted net profit after tax rose 7% to NZ$236 million. Chief executive David Bortolussi said innovative products drove more than half of the sales growth.
Revenue from China and Asia reached NZ$1.448 billion, up 11.2% and representing 73.3% of total revenue. North American revenue grew 28.6% to NZ$179 million, with the family nutrition segment expanding 59.9%.
Commentary
a2 Milk's 12.4% revenue growth masks a shift in growth drivers toward innovative products and family nutrition, which expanded 59.9%. China and Asia still account for 73.3% of total revenue, but for New Zealand SMEs, the takeaway is twofold. First, relying on a single infant formula category is increasingly risky; diversification into adult nutrition and liquid milk can hedge against falling Chinese birth rates.
Second, a2's approval for Chinese-labelled products and capacity release at its Pokeno plant may boost local supply chain demand, offering co-manufacturing or ingredient opportunities for smaller suppliers. North American growth of 28.6% suggests further penetration of the A2 protein concept is possible. However, the decline in daigou and English-labelled infant formula highlights the unsustainability of grey-channel sales.
Local firms should evaluate potential synergies with a2, including packaging, logistics, or specialty ingredient supply.
Keywords: a2 Milk Company, FY2026, revenue, New Zealand dollar, Chinese market, infant formula, family nutrition, EBITDA, innovative products
Source: Nil
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.
